Request To Download Free Sample of This Strategic Report @ Highlighted with 41 tables and 85 figures, this 159-page report ?Asia Pacific Biopharmaceuticals Market 2023-2033 by Product Type, Testing ...
Request To Download Free Sample of This Strategic Report @ Highlighted with 43 tables and 86 figures, this 160-page report ?Europe Biopharmaceuticals Market 2023-2033 by Product Type, Testing Service ...
Vertex Pharmaceuticals ( VRTX 2.53%) has long been known as the company to turn to for life-saving cystic fibrosis (CF) drugs ...
Vertex Pharmaceuticals (NASDAQ:VRTX), a leading biotechnology company known for its cystic fibrosis (CF) treatments, is at a critical juncture as it seeks to diversify its portfolio and maintain its ...
Vertex Pharmaceuticals (VRTX) ended the recent trading session at $470.37, demonstrating a +1.88% swing from the preceding day's closing price. The stock's change was more than the S&P 500's daily ...
On Jan. 30, the U.S. Food and Drug Administration (FDA) approved a new drug called suzetrigine to treat moderate-to-severe ...
Leerink Partners analyst David Risinger has reiterated their bullish stance on VRTX stock, giving a Buy rating on January 31.Maximize Your ...
Apple stock rises after the tech giant posts better-than-expected earnings and guides for solid growth, Intel edges higher after revenue projections miss analysts’ estimates, and Chevron posts ...
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...
The FDA has approved a new type of pain pill designed to eliminate the risks of addiction and overdose associated with opioid medications like Vicodin and OxyContin, the first of its kind in 20 years.
Friday's edition of Forbes Daily covers the investigation of the deadly plane crash, OpenAI's whopping valuation, sluggish ...
Shares of Vertex Pharmaceuticals Inc. surged ahead of Friday's market open after the Food and Drug Administration approved the company's non-opioid pain treatment.